Genfit (GNFT) Competitors $3.80 +0.08 (+2.15%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends GNFT vs. TRDA, CRGX, AUTL, RLAY, PRTA, CRON, RAPP, EOLS, ANAB, and CGEMShould you be buying Genfit stock or one of its competitors? The main competitors of Genfit include Entrada Therapeutics (TRDA), CARGO Therapeutics (CRGX), Autolus Therapeutics (AUTL), Relay Therapeutics (RLAY), Prothena (PRTA), Cronos Group (CRON), Rapport Therapeutics (RAPP), Evolus (EOLS), AnaptysBio (ANAB), and Cullinan Therapeutics (CGEM). These companies are all part of the "pharmaceutical products" industry. Genfit vs. Entrada Therapeutics CARGO Therapeutics Autolus Therapeutics Relay Therapeutics Prothena Cronos Group Rapport Therapeutics Evolus AnaptysBio Cullinan Therapeutics Genfit (NASDAQ:GNFT) and Entrada Therapeutics (NASDAQ:TRDA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, community ranking, dividends, earnings, profitability and institutional ownership. Which has stronger valuation and earnings, GNFT or TRDA? Entrada Therapeutics has higher revenue and earnings than Genfit. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenfit$76.06M2.50-$31.27MN/AN/AEntrada Therapeutics$215.23M3.06-$6.68M$1.5911.06 Which has more volatility & risk, GNFT or TRDA? Genfit has a beta of 1.14, suggesting that its stock price is 14% more volatile than the S&P 500. Comparatively, Entrada Therapeutics has a beta of -0.18, suggesting that its stock price is 118% less volatile than the S&P 500. Does the media favor GNFT or TRDA? In the previous week, Entrada Therapeutics had 1 more articles in the media than Genfit. MarketBeat recorded 1 mentions for Entrada Therapeutics and 0 mentions for Genfit. Entrada Therapeutics' average media sentiment score of 0.42 beat Genfit's score of 0.00 indicating that Entrada Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Genfit Neutral Entrada Therapeutics Neutral Is GNFT or TRDA more profitable? Entrada Therapeutics has a net margin of 25.53% compared to Genfit's net margin of 0.00%. Entrada Therapeutics' return on equity of 16.11% beat Genfit's return on equity.Company Net Margins Return on Equity Return on Assets GenfitN/A N/A N/A Entrada Therapeutics 25.53%16.11%10.39% Does the MarketBeat Community believe in GNFT or TRDA? Genfit received 50 more outperform votes than Entrada Therapeutics when rated by MarketBeat users. However, 81.82% of users gave Entrada Therapeutics an outperform vote while only 69.39% of users gave Genfit an outperform vote. CompanyUnderperformOutperformGenfitOutperform Votes6869.39% Underperform Votes3030.61% Entrada TherapeuticsOutperform Votes1881.82% Underperform Votes418.18% Do analysts recommend GNFT or TRDA? Genfit currently has a consensus target price of $13.00, suggesting a potential upside of 242.11%. Entrada Therapeutics has a consensus target price of $25.67, suggesting a potential upside of 45.92%. Given Genfit's higher probable upside, equities analysts clearly believe Genfit is more favorable than Entrada Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genfit 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Entrada Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25 Do institutionals and insiders hold more shares of GNFT or TRDA? 2.2% of Genfit shares are held by institutional investors. Comparatively, 86.4% of Entrada Therapeutics shares are held by institutional investors. 4.2% of Genfit shares are held by insiders. Comparatively, 7.6% of Entrada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. SummaryEntrada Therapeutics beats Genfit on 14 of the 17 factors compared between the two stocks. Ad Crypto Swap ProfitsURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life-changing for those who are prepared. Why? Because altcoin prices are about to explode.>> Register for the Workshop Now Get Genfit News Delivered to You Automatically Sign up to receive the latest news and ratings for GNFT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNFT vs. The Competition Export to ExcelMetricGenfitBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$185.97M$2.94B$5.12B$9.07BDividend YieldN/A1.90%4.91%4.22%P/E RatioN/A46.7391.3417.19Price / Sales2.50411.851,116.59116.80Price / CashN/A182.1042.6437.86Price / Book2.573.894.794.78Net Income-$31.27M-$42.21M$120.07M$225.60M7 Day Performance-0.52%-2.14%-1.89%-1.24%1 Month Performance-10.38%4.21%11.45%3.36%1 Year Performance4.40%18.40%30.61%16.58% Genfit Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNFTGenfit1.2045 of 5 stars$3.80+2.2%$13.00+242.1%+2.2%$185.97M$76.06M0.00120Positive NewsTRDAEntrada Therapeutics2.8936 of 5 stars$21.41-0.8%$25.67+19.9%+17.3%$801.16M$129.01M13.63110Positive NewsGap DownCRGXCARGO Therapeutics1.4673 of 5 stars$17.25-6.6%$31.80+84.3%-20.0%$794.02MN/A0.00116AUTLAutolus Therapeutics2.5563 of 5 stars$2.98+1.4%$10.40+249.0%-58.4%$792.95M$1.70M0.00330RLAYRelay Therapeutics2.2561 of 5 stars$4.73+2.6%$20.50+333.4%-60.4%$791.71M$25.55M0.00304Insider TradePRTAProthena1.6269 of 5 stars$14.70+4.6%$61.86+320.8%-58.8%$791.01M$91.37M0.00173Analyst ForecastNews CoverageCRONCronos Group1.8381 of 5 stars$2.06+1.0%$3.00+45.6%+4.8%$787.53M$111.23M-15.62356News CoverageRAPPRapport Therapeutics1.5264 of 5 stars$21.27+4.0%$35.00+64.6%N/A$778.06MN/A0.00N/AEOLSEvolus3.8301 of 5 stars$12.27-3.1%$23.00+87.4%+12.5%$776.94M$202.09M0.00170ANABAnaptysBio2.3058 of 5 stars$24.71-0.4%$54.64+121.1%-25.4%$751.93M$17.16M0.00100Analyst ForecastCGEMCullinan Therapeutics1.7981 of 5 stars$12.87-1.5%$31.67+146.1%+32.7%$749.42M$18.94M-4.5330News Coverage Related Companies and Tools Related Companies Entrada Therapeutics Alternatives CARGO Therapeutics Alternatives Autolus Therapeutics Alternatives Relay Therapeutics Alternatives Prothena Alternatives Cronos Group Alternatives Rapport Therapeutics Alternatives Evolus Alternatives AnaptysBio Alternatives Cullinan Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:GNFT) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genfit S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genfit With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
